Ubs Group Ag Biomarin Pharmaceutical Inc Put Options Transaction History

Ubs Group Ag

13 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $2.67 Million - $3.63 Million	38,700 Added 516.0%	46,200 $3.25 Million
Q1 2024 May 13, 2024	BUY	$83.81 - $99.0 $628,575 - $742,500	7,500 New	7,500 $655,000
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $832,128 - $962,880	9,600 New	9,600 $832,000
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $394,460 - $503,085	-5,500 Reduced 21.57%	20,000 $1.77 Million
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $4.89 Million - $5.59 Million	-65,400 Reduced 71.95%	25,500 $1.97 Million
Q2 2021 Aug 13, 2021	BUY	$75.51 - $84.79 $4.41 Million - $4.95 Million	58,400 Added 179.69%	90,900 $7.59 Million
Q1 2021 May 12, 2021	BUY	$74.73 - $90.69 $1.68 Million - $2.04 Million	22,500 Added 225.0%	32,500 $2.45 Million
Q3 2020 Nov 12, 2020	SELL	$71.87 - $131.03 $1.69 Million - $3.08 Million	-23,500 Reduced 70.15%	10,000 $761,000
Q1 2020 May 01, 2020	SELL	$71.37 - $96.85 $1.18 Million - $1.6 Million	-16,500 Reduced 33.0%	33,500 $2.83 Million
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $1.61 Million - $2.16 Million	-25,000 Reduced 33.33%	50,000 $4.23 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $1.35 Million - $1.7 Million	20,000 Added 36.36%	75,000 $5.06 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $4.13 Million - $4.83 Million	51,400 Added 1427.78%	55,000 $4.71 Million
Q1 2019 May 14, 2019	BUY	$84.2 - $98.62 $303,120 - $355,032	3,600 New	3,600 $320,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.